A Sharp investment

Sharp Clinical Services has announced a £9 million investment that will fund a new multiple-phase pharmaceutical manufacturing, packaging and distribution facility in Wales. The investment also includes £500,000 from the Welsh government.

The initial phase of the expansion will involve the acquisition and renovation of a 110,000 square foot facility within the 10 acre site in Rhymney and is expected to be completed by late 2018. This will replace the company’s existing site in Crickhowell and is expected to triple the company’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.

“We are currently working at capacity at our site in Crickhowell, so this investment gives us a blank canvas to design a modern contract packaging, manufacturing and distribution facility that meets the evolving need of drug development companies with single or multiple products at any clinical stage,” said Frank Lis, president of Sharp Clinical Services. “The move to the Rhymney site will enable us to offer expanded capacity, scalability and automation, meaning we can simultaneously support multiple large scale Phase III studies, as well as projects at an earlier trial stage.”